125 related articles for article (PubMed ID: 17976520)
1. Epigenetic control of PRV-1 expression on neutrophils.
Jelinek J; Li J; Mnjoyan Z; Issa JP; Prchal JT; Afshar-Kharghan V
Exp Hematol; 2007 Nov; 35(11):1677-83. PubMed ID: 17976520
[TBL] [Abstract][Full Text] [Related]
2. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
3. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
4. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
5. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
[TBL] [Abstract][Full Text] [Related]
6. The effect of the JAK2 V617F mutation on PRV-1 expression.
Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
[TBL] [Abstract][Full Text] [Related]
7. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
[TBL] [Abstract][Full Text] [Related]
8. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
[TBL] [Abstract][Full Text] [Related]
9. The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NB1, are alleles of a single gene, CD177, in chromosome band 19q13.31.
Caruccio L; Bettinotti M; Director-Myska AE; Arthur DC; Stroncek D
Transfusion; 2006 Mar; 46(3):441-7. PubMed ID: 16533288
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia.
Martini M; Teofili L; Larocca LM
Methods Mol Med; 2006; 125():265-73. PubMed ID: 16502591
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F mutation and PRV-1 overexpression: relevance in the diagnosis of polycythaemia vera and essential thrombocythaemia.
Melis S; Vellinga S; Zachée P; Sierens AC; De Schouwer PJ
Acta Clin Belg; 2009; 64(5):429-33. PubMed ID: 19999391
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders.
Passamonti F; Pietra D; Malabarba L; Rumi E; Della Porta MG; Malcovati L; Bonfichi M; Pascutto C; Lazzarino M; Cazzola M
Br J Haematol; 2004 Sep; 126(5):650-6. PubMed ID: 15327515
[TBL] [Abstract][Full Text] [Related]
13. Instability of PRV-1 mRNA: a factor to be considered in PRV-1 quantification for the diagnosis of polycythemia vera.
Jelinek J; Jedlickova K; Guan Y; Prchal JT
Haematologica; 2004 Jun; 89(6):749-51. PubMed ID: 15194544
[TBL] [Abstract][Full Text] [Related]
14. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.
Griesshammer M; Klippel S; Strunck E; Temerinac S; Mohr U; Heimpel H; Pahl HL
Ann Hematol; 2004 Jun; 83(6):364-70. PubMed ID: 15034760
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.
Teofili L; Martini M; Luongo M; Di Mario A; Leone G; De Stefano V; Larocca LM
J Clin Oncol; 2002 Oct; 20(20):4249-54. PubMed ID: 12377969
[TBL] [Abstract][Full Text] [Related]
16. Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines.
Dillon M; Minear J; Johnson J; Lannutti BJ
Leuk Res; 2008 May; 32(5):811-9. PubMed ID: 17980909
[TBL] [Abstract][Full Text] [Related]
17. PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia.
Passamonti F; Pietra D; Rumi E; Arcaini L; Della Porta MG; Malcovati L; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2005 May; 19(5):888-9. PubMed ID: 15744342
[No Abstract] [Full Text] [Related]
18. Expression of polycythemia rubra vera-1 decreases the dependency of cells on growth factors for proliferation.
Mnjoyan Z; Li J; Afshar-Kharghan V
Haematologica; 2005 Mar; 90(3):405-6. PubMed ID: 15749675
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates.
Sirhan S; Lasho TL; Elliott MA; Tefferi A
Haematologica; 2005 Mar; 90(3):406-8. PubMed ID: 15749676
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.
Tefferi A; Lasho TL; Wolanskyj AP; Mesa RA
Blood; 2004 May; 103(9):3547-8. PubMed ID: 14701686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
